Bone morphogenetic protein 9 regulates tumor growth of osteosarcoma cells through the Wnt/β-catenin pathway

Oncology Reports

Volumn 31, Issue 2, 2014, Pages 989-994

  Lv, Zilan ^a   Wang, Chuan ^b   Yuan, Taixian ^a   Liu, Yuehong ^c   Song, Tao ^a   Liu, Yueliang ^a   Chen, Chu ^a   Yang, Min ^a   Tang, Zuchuan ^a   Shi, Qiong ^a   Weng, Yaguang ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Third People's Hospital of Chongqing   (China)

^c Fourth Hospital of Xi'an City   (China)

Author keywords

catenin; Bone morphogenetic protein 9; c myc; Osteoprotegerin; Osteosarcoma

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN 9; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; MYC PROTEIN; OSTEOPROTEGERIN; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; GROWTH REGULATION; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; WNT SIGNALING PATHWAY;

ACTINS; ANTIBODIES; APOPTOSIS; BETA CATENIN; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; DOWN-REGULATION; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; GROWTH DIFFERENTIATION FACTORS; HEK293 CELLS; HUMANS; OSTEOPROTEGERIN; OSTEOSARCOMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; WNT SIGNALING PATHWAY;

EID: 84892388703     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2931     Document Type: Article

References (32)

1. Young JL Jr and Miller RW: Incidence of malignant tumors in U.S. children. J Pediatr 86: 254-258, 1975.
2. Fagioli F, Biasin E, Mereuta OM, et al: Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow Transpl 41: S131-S134, 2008.
3. Barker N: The canonical Wnt/beta-catenin signalling pathway. Methods Mol Biol 468: 5-15, 2008.
4. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480, 2006.
5. Behrens J: Control of beta-catenin signaling in tumor development. Ann NY Acad Sci 910: 21-35, 2000.
6. Haydon RC, Deyrup A, Ishikawa A, et al: Cytoplasmic and/or nuclear accumulations of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 102: 338-342, 2002.
7. Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T and Mukai K: Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis 20: 525-529, 2003.
8. MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26, 2009.
9. McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X and Hoang BH: The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev Anticancer Ther 11: 1223-1232, 2011.
10. Sato MM, Nakashima A, Nashimoto M, Yawaka Y and Tamura M: Bone morphogenetic protein-2 enhances Wnt/beta-catenin signaling-induced osteoprotegerin expression. Genes Cells 14: 141-153, 2009.
11. Singh A and Morris RJ: The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev 21: 299-313, 2010.
12. Kim M and Choe S: BMPs and their clinical potentials. BMB Rep 44: 619-634, 2011.
13. Herrera B, van Dinther M, ten Dijke P and Inman GJ: Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res 69: 9254-9262, 2009.
14. Herrera B, García-Álvaro M, Cruz S, et al: BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells. PloS One 8: e69535, 2013.
15. Ye L, Kynaston H and Jiang WG: Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol Cancer Res 6: 1594-1606, 2008.
16. Wang K, Feng H, Ren W, et al: BMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231. J Cancer Res Clin 137: 1687-1696, 2011.
17. Liu Y, Wang W, Xu J, et al: Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Oncol Rep 30: 1723-1730, 2013.
18. Chen D, Zhao M and Mundy GR: Bone morphogenetic proteins. Growth Factors 22: 233-241, 2004.
19. Grcevic D, Kusec R, Kovacic N, et al: Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes. Leukemia Res 34: 742-751, 2010.
20. Wang L, Park P, Zhang H, et al: BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line. Cancer Biol Ther 11: 457-463, 2011.
21. Kang Q, Sun MH, Cheng H, et al: Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 11: 1312-1320, 2004.
22. Lv Z, Yang D, Li J, et al: Bone morphogenetic protein 9 overexpression reduces osteosarcoma cell migration and invasion. Mol Cells 36: 119-126, 2013.
23. Luo J, Chen J, Deng Z-L, et al: Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest 87: 97-103, 2007.
24. Flores RJ, Li Y, Yu A, et al: A systems biology approach reveals common metastatic pathways in osteosarcoma. BMC Syst Biol 6: 50, 2012.
25. Freeman TJ, Smith JJ, Chen X, et al: Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin. Gastroenterology 142: 562-571, 2012.
26. Neville-Webbe HL, Cross NA, Eaton CL, et al: Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 86: 269-279, 2004.
27. Nyambo R, Cross N, Lippitt J, et al: Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res 19: 1712-1721, 2004.
28. Shipman CM and Croucher PI: Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63: 912-916, 2003.
29. Holen I, Cross SS, Neville-Webbe HL, et al: Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - a role in tumour cell survival? Breast Cancer Res Treat 92: 207-215, 2005.
30. Fodde R and Brabletz T: Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 19: 150-158, 2007.
31. Forde JE and Dale TC: Glycogen synthase kinase 3: A key regulator of cellular fate. Cell Mol Life Sci 64: 1930-1944, 2007.
32. Li J, Xing M, Zhu M, et al: Glycogen synthase kinase 3 beta induces apoptosis in cancer cells through increase of survivin nuclear localization. Cancer Lett 272: 91-101, 2008.